mRNA Ä¡·áÁ¦ ¼öʰ³¹ßÁ¦Á¶±â°ü(CDMO) ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : ¿ëµµº°, ÀûÀÀÁõº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)
mRNA Therapeutics Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report By Application, By Indication, By End-use, By Region, And Segment Forecasts, 2024 - 2030
»óǰÄÚµå : 1511801
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2024³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 144 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,609,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,950 £Ü 10,055,000
Printable PDF (5-User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,949,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

mRNA Ä¡·áÁ¦ ¼öʰ³¹ßÁ¦Á¶±â°ü(CDMO) ½ÃÀå ¼ºÀå°ú µ¿Çâ

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, mRNA Ä¡·áÁ¦ ¼öʰ³¹ßÁ¦Á¶±â°ü ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³âºÎÅÍ 2030³â±îÁö 11.28%ÀÇ CAGRÀ» ±â·ÏÇϸç 2030³â±îÁö 83¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

mRNA ¹× ¼¼Æ÷ Àü´Þ ½Ã½ºÅÛÀÇ ±â¼ú ¹ßÀüÀº ºñ¿ë È¿À²¼º, Á¦Á¶ÀÇ ¿ëÀ̼º, ÀÌÀü¿¡´Â Ä¡·áÇÒ ¼ö ¾ø¾ú´ø °æ·Î¸¦ Ç¥ÀûÀ¸·Î »ïÀ» ¼ö ÀÖ´Â ´É·Â°ú °áÇÕÇÏ¿© ÀÇ·á¿¡ Çõ¸íÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Â ¹«ÇÑÇÑ ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. mRNA Ä¡·áÁ¦¸¦ °³¹ßÇϱâ À§ÇÑ R&D ÅõÀÚ Áõ°¡¿Í °­·ÂÇÑ Á¦Ç° ÆÄÀÌÇÁ¶óÀεµ ½ÃÀå ¼ºÀå¿¡ ÈûÀ» ½Ç¾îÁÖ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Moderna´Â 2023³â 4ºÐ±â ¿¬±¸°³¹ßºñ°¡ 2022³â µ¿±â ´ëºñ 16% Áõ°¡ÇÑ 14¾ï ´Þ·¯¿¡ ´ÞÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù.

¿¬±¸°³¹ßºñ´Â ȸ»çÀÇ °Å´ë¼¼Æ÷¹ÙÀÌ·¯½º(CMV) ¹é½Å, RSV ¹é½Å, COVID-19¿Í µ¶°¨ È¥ÇÕ ¹é½Å, °³ÀθÂÃãÇü ½ÅÇ׿ø ¿ä¹ýÀ» ÅëÇÑ ÀÓ»ó Á¦Á¶ Ȱµ¿ÀÇ Áõ°¡·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº mRNA Ä¡·áÁ¦¿¡ ´ëÇÑ ¿¬±¸ ³ë·ÂÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ¹ÌÃæÁ· ÀÇ·á ¼ö¿ä¸¦ ÃæÁ·½Ã۱â À§ÇÑ »õ·Î¿î Ä¡·áÁ¦ÀÇ °³¹ßÀÌ Á¦Ç° ½ÃÀå¿¡ º¯È­¸¦ °¡Á®¿À°í ÀÖ½À´Ï´Ù. ºÐÀÚÀÇ º¹À⼺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¿¬±¸ ¹× Á¦Á¶ ¼­ºñ½º¿¡ ´ëÇÑ ½ÉÃþÀûÀÎ Áö½Ä°ú »õ·Î¿î ºÐÀÚ Æ÷¸ËÀÇ Áö¼Ó°¡´ÉÇÑ ¹ßÇö ¹× ½ºÄÉÀϾ÷À» °¡´ÉÇÏ°Ô ÇÏ´Â ±â¼ú¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÄÁÁê°ÔÀ̼ÇÀ̳ª ÀÌÁ߯¯À̼º Ç×ü Á¦ÀÛ°ú °°Àº Ç÷§Æû ±â¼úÀº °³¹ß ±â°£°ú »ý»ê ±â°£À» Å©°Ô ´ÜÃàÇÒ ¼ö ÀÖ¾î, °í°´µéÀº ½ÃÀå Ãâ½Ã ±â°£À» ´ÜÃàÇϰí ÅõÀÚ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖ´Â ¼÷·ÃµÈ CDMO¸¦ ¿øÇϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó Á¦¾à ¹× »ý¸í°øÇÐ »ê¾÷À» À§ÇÑ Á¦Ç°À» ¼³°è ¹× Á¦Á¶ÇÏ´Â CDMO¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù.

mRNA Ä¡·áÁ¦ ¼öʰ³¹ßÁ¦Á¶±â°ü ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå mRNA Ä¡·áÁ¦ ¼öʰ³¹ßÁ¦Á¶±â°ü(CDMO) ½ÃÀå : º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå mRNA Ä¡·áÁ¦ ¼öʰ³¹ßÁ¦Á¶±â°ü(CDMO) ½ÃÀå : ¿ëµµº° ºÐ¼®

Á¦5Àå mRNA Ä¡·áÁ¦ ¼öʰ³¹ßÁ¦Á¶±â°ü(CDMO) ½ÃÀå : ÀûÀÀÁõº° ºÐ¼®

Á¦6Àå mRNA Ä¡·áÁ¦ ¼öʰ³¹ßÁ¦Á¶±â°ü(CDMO) ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ºÐ¼®

Á¦7Àå mRNA Ä¡·áÁ¦ ¼öʰ³¹ßÁ¦Á¶±â°ü(CDMO) ½ÃÀå : Áö¿ªº° ºÐ¼®

Á¦8Àå mRNA Ä¡·áÁ¦ ¼öʰ³¹ßÁ¦Á¶±â°ü(CDMO) ½ÃÀå : °æÀï »óȲ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

mRNA Therapeutics Contract Development & Manufacturing Organization Market Growth & Trends:

The global mRNA therapeutics contract development & manufacturing organization market size is expected to reach USD 8.35 billion by 2030, registering a CAGR of 11.28% from 2024 to 2030, according to a new report by Grand View Research, Inc. Growing technological advancements in mRNA and cellular delivery systems, coupled with their cost effectiveness, manufacturing simplicity, and ability to target previously undruggable pathways, have limitless potential to revolutionize medicine. This could represent lucrative growth opportunities for the market. Increasing R&D investments to develop mRNA therapeutics and a strong product pipeline are also propelling the market's growth. For instance, Moderna shared that R&D expenses for the fourth quarter of 2023 increased by 16% to USD 1.4 billion compared to the same quarter of 2022.

The R&D spending was driven by increased clinical manufacturing activities, with the company's Cytomegalovirus (CMV) vaccine, RSV vaccine, and combination vaccine against COVID-19 & flu, as well as its individualized neoantigen therapy. Such factors are expected to boost research efforts in mRNA therapeutics. In addition, developing novel therapeutics to address unmet medical needs is altering the product market. The rise in molecular complexity drives the need for in-depth knowledge in research and manufacturing services, as well as the technology to enable sustainable expression and scale-up of novel molecular formats. Platform technologies, such as those for bioconjugation or the creation of bispecific antibodies, can drastically shorten development and production times, and customers are looking for skilled CDMOs who can assist them shorten the time to market and reducing investment risk. Consequently, the need for CDMOs to design and produce goods for the pharmaceutical and biotechnology industries is growing exponentially.

mRNA Therapeutics Contract Development & Manufacturing Organization Market Report Highlights:

Table of Contents

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Variables, Trends, & Scope

Chapter 4 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Application Analysis

Chapter 5 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Indication Analysis

Chapter 6 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: End-use Analysis

Chapter 7 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Regional Analysis

Chapter 8 mRNA Therapeutics Contract Development & Manufacturing Organization (CDMO) Market: Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â